Harvard Bioscience raises FY2026 revenue growth outlook to 3%-5%

Reuters2026/08/11 11:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Harvard Apparatus Regenerative Technology raised full-year 2026 revenue guidance to 3%-5% year-over-year growth.
Adjusted gross margin expected at 57%-59%, reflecting higher volume of lower-margin CMT products, plus geographic mix.
Adjusted EBITDA growth forecast at 6%-10%; target maintained as sales momentum offsets mix-related margin pressure.
Third-quarter revenue outlook set at USD 21 million-USD 22.6 million; adjusted EBITDA seen at USD 1.5 million-USD 2.5 million.
Guidance follows second-quarter revenue of USD 22.7 million, up 11% year over year; adjusted EBITDA rose to USD 1.7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Apparatus Regenerative Technology Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Harvard Bioscience raises FY2026 revenue growth outlook to 3%-5%

You may also like

Crypto prices